Key points are not available for this paper at this time.
Although artificial and non-nutritive sweeteners are widely used and generally recognized as safe by the US and European Union regulatory agencies, there have been no clinical trials to assess either long-term cardiovascular disease risks or short-term cardiovascular disease-relevant phenotypes. Recent studies report that fasting plasma levels of erythritol, a commonly used sweetener, are clinically associated with heightened incident cardiovascular disease risks and enhance thrombosis potential in vitro and in animal models. Effects of dietary erythritol on thrombosis phenotypes in humans have not been examined.
Building similarity graph...
Analyzing shared references across papers
Loading...
Marco Witkowski
Cleveland Clinic
Jennifer Wilcox
Cleveland Clinic
Valesha M. Province
Cleveland Clinic
Arteriosclerosis Thrombosis and Vascular Biology
Cleveland Clinic
Charité - Universitätsmedizin Berlin
German Centre for Cardiovascular Research
Building similarity graph...
Analyzing shared references across papers
Loading...
Witkowski et al. (Thu,) studied this question.
synapsesocial.com/papers/68e5cfeeb6db643587565e98 — DOI: https://doi.org/10.1161/atvbaha.124.321019
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: